Relationship between platelet and urinary 8-Iso-PGF2α levels in subjects with different degrees of NOX2 regulation
Roberto Carnevale, Luigi Iuliano, Cristina Nocella, Simona Bartimoccia, Stefano Trapè, Roberta Russo, Maria Cristina Gentile, Roberto Cangemi, Lorenzo Loffredo, Pasquale Pignatelli, Francesco Violi, IPINET group, Roberto Carnevale, Luigi Iuliano, Cristina Nocella, Simona Bartimoccia, Stefano Trapè, Roberta Russo, Maria Cristina Gentile, Roberto Cangemi, Lorenzo Loffredo, Pasquale Pignatelli, Francesco Violi, IPINET group
Abstract
Background: Urinary 8-iso-PGF2α, a marker of oxidative stress, is influenced by the activation of NOX2. It is unclear if platelets 8-iso-PGF2α contribute to urinary 8-iso-PGF2α.
Methods and results: In a cross-sectional study, platelet, urinary, and serum 8-iso-PGF2α were determined in subjects with downregulation (X-linked chronic granulomatous disease [X-CGD], n=25) and upregulation (type II diabetic patients [T2D], n=121) of NOX2 and 153 controls matched for sex and age. In diabetic patients (n=18), the above variables were repeated before and after 7 days treatment with 100 mg/day aspirin or 100 mg/day aspirin plus 40 mg/day atorvastatin. In vitro study was performed to see the contribution of blood cells to serum 8-iso-PGF2α. Compared with controls, X-CGD patients had lower platelet, serum, and urinary 8-iso-PGF2α values; conversely, diabetic patients had higher values of 8-iso-PGF2α compared with controls. Urinary 8-iso-PGF2α significantly correlated with both platelet and serum 8-iso-PGF2α in the 2 cohorts. A parallel increase of platelet, serum, and urinary 8-iso-PGF2α by aspirin and a parallel decrease by aspirin plus atorvastatin were detected in the interventional study. In vitro study demonstrated that platelets contribute to 37% of serum 8-iso-PGF2α and that only 13% of it is of extravascular origin.
Conclusions: The study suggests that NOX2 contributes to the formation of 8-iso-PGF2α in both platelets and urine. The direct correlation between platelet and urinary 8-iso-PGF2α suggests that, at least partly, urinary 8-iso-PGF2α reflects platelet 8-iso-PGF2α production. Analysis of serum 8-iso-PGF2α may represent a novel tool to investigate the production of 8-iso-PGF2α by blood cells including platelets.
Clinical trial registration: URL: ClinicalTrials.gov. Unique Identifier: NCT01250340.
Keywords: 8‐iso‐PGF2α; NOX2; oxidative stress; platelets.
Figures
References
- Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2‐like compounds are produced in vivo in humans by a non‐cyclooxygenase, free radical‐catalyzed mechanism. Proc Natl Acad Sci. 1990; 87:9383-9387
- Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low‐dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353:2373-2383
- Pignatelli P, Carnevale R, Di Santo S, Bartimoccia S, Sanguigni V, Lenti L, Finocchi A, Mendolicchio L, Sorresina AR, Plebani A, Violi F. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol. 2011; 31:423-434
- Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: part II: animal and human studies. Circulation. 2003; 108:2034-2040
- Davì G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin‐6 and disease duration. Circulation. 2003; 107:3199-3203
- Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, Patrono C. In vivo formation of 8‐Epi‐prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997; 17:3230-3235
- Violi F, Sanguigni V, Carnevale R, Plebani A, Rossi P, Finocchi A, Pignata C, De Mattia D, Martire B, Pietrogrande MC, Martino S, Gambineri E, Soresina AR, Pignatelli P, Martino F, Basili S, Loffredo L. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation. 2009; 120:1616-1622
- Cangemi R, Pignatelli P, Carnevale R, Nigro C, Proietti M, Angelico F, Lauro D, Basili S, Violi F. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes. 2012; 6:1626-1632
- Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, Rossi P, Gattorno M, Rabusin M, Azzari C, Dellepiane RM, Pietrogrande MC, Trizzino A, Di Bartolomeo P, Martino S, Carpino L, Cossu F, Locatelli F, Maccario R, Pierani P, Putti MC, Stabile A, Notarangelo LD, Ugazio AG, Plebani A, De Mattia D. Clinical features, long term follow‐up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol. 2008; 126:155-164
- American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011; 34Suppl 1:S62-9.2
- Sircar D, Subbaiah PV. Isoprostane measurement in plasma and urine by liquid chromatography‐mass spectrometry with one‐step sample preparation. Clin Chem. 2007; 53:251-258
- Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, Basili S, Violi F. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2010; 30:360-367
- Carnevale R, Pignatelli P, Di Santo S, Bartimoccia S, Sanguigni V, Napoleone L, Tanzilli G, Basili S, Violi F. Atorvastatin inhibits oxidative stress via adiponectin‐mediated NADPH oxidase down‐regulation in hypercholesterolemic patients. Atherosclerosis. 2010; 213:225-234
Source: PubMed